Is there a changing paradigm in the management of patients with relapsed or refractory HL?

FAQ published on April 5, 2016
Download Transcript
Robert W. Chen, MD
Assistant Professor of Medicine
Department of Hematology
& Hematopoietic Cell Transplantation
City of Hope
Duarte, California
Is there a changing paradigm in the management of patients with relapsed or refractory HL?

Managing HL recently talked with Dr. Robert Chen, an assistant professor at the City of Hope National Medical Center in Duarte, California, and co-leader of a leading lymphoma disease team. MHL asked Dr. Chen if he has seen a change in the treatment paradigm for patients with relapsed or refractory Hodgkin lymphoma in recent years.

Dr. Chen: The answer to this question is yes. For patients who have relapsed or refractory Hodgkin lymphoma following induction chemotherapy, the typical standard approach has been to give a multi-agent combination chemotherapy, such as ICE or ESHAP, before the patient received autologous stem cell transplant (ASCT). Today, however, more and more oncologists are using a brentuximab vedotin-based approach.

There are three different methods that are being used with this agent. The first is a sequential approach; for example, the patient can get single-agent brentuximab vedotin at the outset. If they achieve a complete response (CR), they can go directly into ASCT. Alternatively, if the patient does not achieve CR after brentuximab vedotin therapy, they can undergo multi-agent salvage chemotherapy such as ICE. With this approach, they will have two opportunities to achieve CR before going to transplant.

The second method is to add brentuximab vedotin to bendamustine. At ASH 2015, Dr. Ann LaCasce presented a study (ASH 2015 abstract 3982) which indicated that an outpatient regimen of brentuximab vedotin in combination with bendamustine resulted in a very high CR rate. The data suggested that the brentuximab-bendamustine combination may be a promising salvage regimen for Hodgkin lymphoma patients who have experienced their first relapse.

The third strategy being used today is to add brentuximab vedotin to other novel agents, such as PD-1 or PD-L1 inhibitor. Two of these agents are undergoing phase 1 and phase 2 testing right now. Currently, our group is conducting a trial using brentuximab vedotin plus nivolumab in this setting [NCT02572167; NCT01896999].

Thank you.

For further information, please refer to the related resources and activities on the ManagingHL.com website, as identified below.

Last modified: March 4, 2016
Related Items by Author
What new/emerging treatments for relapsed/refractory HL are most likely to improve patient outcomes?
Robert W. Chen, MD
FAQ published on September 6, 2016
What treatment approaches may increase chances for a higher cure rate in patients with R/R HL?
Robert W. Chen, MD
FAQ published on July 7, 2016

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved